Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932697 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
A Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 2
- Study locations
NCT01932697 is a Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma that has completed, run by Mayo Clinic. The registered enrollment target is 81 participants, below the 1,314-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01932697, a Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy with docetaxel my kill more tumor cells.
Conditions Studied
Interventions
- DRUG Docetaxel
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- RADIATION Intensity-Modulated Radiation Therapy
- RADIATION Hyperfractionation
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-09-04 |
| Est. Completion | 2021-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932697
The ClinicalTrials.gov registry entry for NCT01932697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,314-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT01932697 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01932697 about?
NCT01932697 is a clinical study titled "Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer". This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop th...
What is the current status of trial NCT01932697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2013-09-04. Estimated completion is 2021-12-28.
What conditions does trial NCT01932697 study?
This clinical trial studies the following conditions: Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT01932697?
The interventions under investigation include: Docetaxel (DRUG), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Intensity-Modulated Radiation Therapy (RADIATION), Hyperfractionation (RADIATION).
Who is sponsoring clinical trial NCT01932697?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01932697 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
RECRUITING · NA
-
Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Human Papillomavirus Infection
All registered trials for this condition
Stage I Oropharyngeal Squamous Cell Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.